Real-world assessment of liver corrected T1 and magnetic resonance elastography in predicting liver disease progression.

Guidelines prioritise early detection of chronic liver disease progression risk. To avoid biopsy, NITs have become part of standard‐of‐care. Across etiologies, patients with low fibrosis risk by MRE but high disease activity by cT1 have ~threefold higher progression, showing cT1 flags risk earlier than stiffness alone. Integrating cT1 into care pathways improves stratification and proactive management without biopsy.